BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Caplyta (Lumateperone) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Caplyta (Lumateperone)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06482554-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06482554)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Schizophrenia.\nStudy: Lumat
 eperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
 \nEstimated primary completion: December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lumateperone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06482554
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06174116-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Caplyta (Lumateperone): Phase 4 readout est. (NCT06174116)
DESCRIPTION:Caplyta (Lumateperone)\, phase 4\, Schizophrenia.\nStudy: Metab
 olic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Pat
 ients With Schizophrenia\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06174116
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676669-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Caplyta (Lumateperone): Phase 4 readout est. (NCT07676669)
DESCRIPTION:Caplyta (Lumateperone)\, phase 4.\nStudy: This Study Aims to Co
 mpare the Efficacy and Safety of Lumateperone and Cariprazine in Patients 
 With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale
  (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) 
 and Recording Treatment Emergent Adverse Effects\nEstimated primary comple
 tion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lum
 ateperone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07676669
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850689-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT05850689)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: Study of Lumateperone as Adjunctive Therapy in the Treatment of Pat
 ients With Major Depressive Disorder\nEstimated primary completion: 5 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0585
 0689
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706674-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06706674)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder (ASD) in Pediatric Patients\nEstimated primary completion: 2
 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumatepe
 rone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06706674
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06690398-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06690398)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder in Pediatric Patients\nEstimated primary completion: 21 June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06690
 398
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734103-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Caplyta (Lumateperone): Phase 2 readout est. (NCT07734103)
DESCRIPTION:Caplyta (Lumateperone)\, phase 2.\nStudy: Lumateperone in the T
 reatment of Stuttering\, Childhood Onset Fluency Disorder\nEstimated prima
 ry completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/lumateperone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07734103
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824206-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Caplyta (Lumateperone): Phase 4 readout est. (NCT07824206)
DESCRIPTION:Caplyta (Lumateperone)\, phase 4\, Major Depressive Disorder.\n
 Study: Lumateperone Added to Antidepressant Therapy in Adults With Major D
 epressive Disorder Experiencing Emotional Blunting\nEstimated primary comp
 letion: January 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lumateperone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07824206
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699445-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Caplyta (Lumateperone): Phase 4 readout est. (NCT07699445)
DESCRIPTION:Caplyta (Lumateperone)\, phase 4\, Bipolar Depression.\nStudy: 
 The Effects of Lumateperone on Obesity and Physiologic Aging and Their Ass
 ociation With Antidepressant Response in Bipolar Depression\nEstimated pri
 mary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lumateperone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07699445
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799493-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280518
DTEND;VALUE=DATE:20280519
SUMMARY:Caplyta (Lumateperone): Phase 4 readout est. (NCT07799493)
DESCRIPTION:Caplyta (Lumateperone)\, phase 4.\nStudy: Caplyta Versus Placeb
 o for Adults With Social Anxiety Disorder\nEstimated primary completion: 1
 8 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateper
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07799493
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623135-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT07623135)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: Lumateperone for Late-Life Depression\nEstimated primary completion
 : June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumatepe
 rone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07623135
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747389-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT07747389)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: A Study of Lumateperone Versus Placebo in Participants With Major D
 epressive Disorder\nEstimated primary completion: 20 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07747389
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369115-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Caplyta (Lumateperone): Phase 4 readout est. (NCT07369115)
DESCRIPTION:Caplyta (Lumateperone)\, phase 4\, Major Depressive Disorder.\n
 Study: Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctiv
 e Therapy for Major Depressive Disorder and History of Early Life Abuse\nE
 stimated primary completion: January 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lumateperone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07369115
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948031-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Caplyta (Lumateperone): Phase 4 readout est. (NCT07948031)
DESCRIPTION:Caplyta (Lumateperone)\, phase 4\, Major Depressive Disorder.\n
 Study: Lumateperone Monotherapy Versus Usual Antidepressant Treatment for 
 First-Episode Depression\nEstimated primary completion: May 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07948031
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372964-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06372964)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Bipolar Depression.\nStudy: 
 Multicenter Study of Lumateperone for the Treatment of Bipolar Depression 
 in Pediatric Patients\nEstimated primary completion: 31 October 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06372964
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229210-872@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20320428
DTEND;VALUE=DATE:20320429
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06229210)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Schizophrenia.\nStudy: Safet
 y and Tolerability Trial of Lumateperone in Pediatric Patients With Schizo
 phrenia\, Bipolar Disorder or Autism Spectrum Disorder\nEstimated primary 
 completion: 28 April 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lumateperone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06229210
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
